SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Norris Medicines - Quaterly Results

11 Nov 2022 Evaluate
The sales figure stood at Rs. 30.28 millions for the September 2022 quarter. The mentioned figure indicates a growth of about 37.70% as compared to Rs. 21.99 millions during the year-ago period.The Net Loss for the quarter ended September 2022 is Rs. -5.63 millions as compared to Net Loss of Rs. -7.89 millions of corresponding quarter ended September 2021 Operating profit Margin for the quarter ended September 2022 improved to 2.36% as compared to -1.28% of corresponding quarter ended September 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 30.28 21.99 37.70 39.81 70.92 -43.87 94.38 122.51 -22.96
Other Income 0.00 0.00 0.00 0.00 0.16 0.00 0.26 0.50 -48.00
PBIDT 2.36 -1.28 -284.38 0.41 4.04 -89.85 -0.46 -16.91 -97.28
Interest 6.48 4.99 29.86 7.41 9.24 -19.81 14.82 16.34 -9.30
PBDT -4.12 -6.27 -34.29 -7.00 -5.20 34.62 -15.28 -33.25 -54.05
Depreciation 1.51 1.62 -6.79 3.02 3.23 -6.50 6.57 6.67 -1.50
PBT -5.63 -7.89 -28.64 -10.02 -8.43 18.86 -21.85 -39.92 -45.27
TAX 0.00 0.00 0.00 0.00 0.00 0.00 10.79 9.69 11.35
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 10.79 9.69 11.35
PAT -5.63 -7.89 -28.64 -10.02 -8.43 18.86 -32.64 -49.61 -34.21
Equity 99.26 99.26 0.00 99.26 99.26 0.00 99.26 99.26 0.00
PBIDTM(%) 7.79 -5.82 -233.90 1.03 5.70 -81.92 -0.49 -13.80 -96.47

Norris Medicines Share Price

14.97 0.22 (1.49%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×